Weight-loss drugs in the GLP-1 class, which include widely used medications like Ozempic, may cut the risk of breast cancer by up to 30 percent, according to new studies reported by The Guardian.
The findings come from multiple research efforts, including a large cohort study that linked GLP-1 use to lower breast cancer incidence. Separate research published by CancerNetwork also suggested GLP-1 receptor agonists may improve survival and reduce immune-related side effects in patients receiving immune checkpoint inhibitor treatment.
GLP-1 drugs, originally developed to treat type 2 diabetes, have become some of the most widely prescribed medications in the world after studies showed significant weight loss results. Researchers have been examining whether their benefits extend beyond metabolism and blood sugar regulation.
Forbes also reported that new research suggests GLP-1 weight loss drugs could stop cancer from progressing. The Conversation noted that while the science on GLP-1 drugs and cancer shows promise, questions remain about what is established science versus what is still emerging.
